Cell

THERAPY

LabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial | Contracts

JOHNSON CITY, Tenn. and NASHVILLE, Tenn., May 6, 2021 /PRNewswire/ — LabConnect, Inc. and Cryoport, Inc. (NASDAQ: CYRX) today announced a partnership to provide comprehensive logistics support for an upcoming Phase I/II clinical trial sponsored by Triumvira Immunologics Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers. The study intends to investigate the safety and efficacy of autologous TAC-T Cells (TAC01-HER2) targeting HER2 in relapsed or refractory solid tumors.

The partnership will integrate Cryoport’s Cryoportal® Logistics Management Platform and LabConnect’s SampleGISTICS™ platform to provide Triumvira with the highest possible available level of tracking and proactive management for their samples, source materials, and therapeutic product. Each step from scheduling, sample collection, confirming courier pickups/deliveries, and monitoring transport will be monitored by LabConnect and Cryoport project management.

LabConnect, the leader in innovative central laboratory services for cell and gene therapy clinical trials,

Read More Read More
THERAPY

CARISMA Therapeutics to Present Data at The American Society of Gene & Cell Therapy 24th Annual Meeting | Tradeshow News

PHILADELPHIA, April 28, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced findings from two studies accepted for virtual presentation at The American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting on Tuesday, May 11Friday, May 14. The findings mark the first time chimeric antigen receptor macrophages (CAR-Ms) have been assessed in a fully immunocompetent animal model and highlight the potential of CAR-monocytes (CAR-Mono) as an innovative and expedited immunotherapeutic pathway.

Dr. Stefano Pierini, Senior Scientist at CARISMA, will present findings from “Chimeric Antigen Receptor Macrophages (CAR-M) Induce Anti-Tumor Immunity and Synergize with Immune Checkpoint Inhibitors in Pre-Clinical Solid Tumor Models,” which established a fully immunocompetent solid tumor mouse model and evaluated the interaction of CAR-M with the tumor microenvironment and the endogenous adaptive immune system. The findings demonstrate that CAR-M therapy showed

Read More Read More
EXERCISE

Lucianne.com News Forum – A cement slab bed, 23 hours a day alonein a 7x10ft cell and one hour for exercise:Derek Chauvin’s new life on suicide watchat Minnesota maximum security prison

by

Megan Sheets

&

Emily Crane

Original Article

Posted By: Imright,

4/22/2021 10:20:45 AM

Derek Chauvin is spending 23 hours a day alone in 7-by-10-foot cell at Minnesota’s only maximum security prison as he awaits sentencing for the murder of George Floyd.
Chauvin, 45, was whisked to the Minnesota Correctional Facility – Oak Park Heights on Tuesday and placed on suicide watch after a jury handed down its guilty verdict. The disgraced former Minneapolis cop will be held in solitary confinement in what’s known as a ‘Super Seg’ single prison cell for the next eight weeks until his sentencing, where he faces up to 40 years.


Reply 1 – Posted by: earlybird 4/22/2021 10:23:32 AM (No. 763357)

Media salivating over this. I think it’s obscene.

72 people like this.

Reply 2 – Posted by: PChristopher 4/22/2021 10:26:37 AM (No. 763368)

I’m with #1

44 people like this.
Read More Read More
SUPPLEMENT

With LIFETAKT CELL ESSENCE, LR is Setting New Dietary Supplement Standards

AHLEN, Germany–(BUSINESS WIRE)–These days, our cells face more challenges than ever due to stress, lack of exercise and environmental influences. LR Health & Beauty has just launched a cutting-edge dietary supplement concept aimed at improving cell health: LR LIFETAKT CELL ESSENCE with the so-called Cell Boost Formula.

The three products focus on food, energy and regeneration. Each product is a carefully balanced composition of various vitamins, minerals and superfoods (e.g. moringa, turmeric or algae) combined with enzymes or ribose. On the one hand, this supports the energy supply and energy conversion1 within the cells as well as cell regeneration2,3. On the other hand, it ensures a basic supply of nutrients and protects against oxidative stress4,5.

“LR LIFETAKT CELL ESSENCE meets people’s need for pioneering health support and for holistic solutions. We use the best ingredients with the aim of promoting our vitality, performance

Read More Read More
THERAPY

Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline | Financing Agreements

PHILADELPHIA, March 3, 2021 /PRNewswire/ — Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of a $160 million Series C financing. The financing was led by Casdin Capital and brought together a syndicate of new investors including Fidelity Management & Research LLC, the Federated Hermes Kauffmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital. Founding investors Versant Ventures and Leaps by Bayer also participated. Eli Casdin, Founder and Chief Investment Officer of Casdin Capital will be joining the Century Therapeutics Board of Directors.

“We are fortunate to be surrounded by such a top-tier group of investors, whose support will enable the acceleration of Century’s technology platform into the clinic,” said Lalo Flores, Chief Executive Officer, Century Therapeutics. “With this new investor partnership, we are well-positioned

Read More Read More